Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 SEK | -3.44% | -8.85% | -97.06% |
05-22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.06% | 45.36M | |
+48.54% | 56.61B | |
+37.49% | 39.25B | |
-6.02% | 39.62B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+31.71% | 12.48B | |
+28.18% | 12.51B | |
+0.38% | 12.2B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma AB Announces Board Changes